Table 1.

Activity and strengths of new antifungals against Candida auris.

Drug	New mechanism	Formulation	Activity against Candida auris			Comments
			In vitro	Animal model	Clinical trials
Rezafungin	−	IV	+ CLSI MIC90 0.25 mg/L73	+77	+	in ReSTORE trial NCT03667690
Fosmanogepix/Manogepix	+	PO, IV	+ CLSI MIC50 0.004 mg/L MIC90 0.031 mg/L39	+35	unk	APEX trial NCT04148287 terminated due to COVID-19
Ibrexafungerp	(+)	PO, (IV)	+ CLSI MIC50 0.12–1 mg/L56 CLSI MIC90 1 mg/L133	+39	+	in CARES trial NCT03363841 interim analysis
VL-2397	+/unk	IV	unk	unk	unk
NP339	+	unk	unk	unk	unk
MAT2203	−	PO	unk	unk	unk
Oteseconazole	−	PO, IV	unk	unk	unk
ATI-2307	+	unk	+ CLSI MIC50 ≤0.008-0.015 mg/L102	+102	unk
Miltefosine	+/unk	PO	+ CLSI MIC50 2-4 mg/L126	+125	unk	Synergistic effect with amphotericin B in vitro